FUDR/Oxaliplatin HAI Plus Irinotecan vs. FOLFOXIRI Chemotherapy in Treating Initially Unresectable CRCLM
Status:
Not yet recruiting
Trial end date:
2022-12-31
Target enrollment:
Participant gender:
Summary
The aim of the trial is to compare the objective response rates of FUDR/Oxaliplatin HAI plus
CPT-11 and FOLFOXIRI chemotherapy in patients with initially non-resectable metastatic
colorectal cancer liver metastases. The patients will be treated with systemic FOLFOXIRI
chemotherapy or FUDR/Oxaliplatin hepatic arterial infusion with CPT-11 systemic chemotherapy.